80 FR 50859 - National Cancer Institute; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 162 (August 21, 2015)

Page Range		50859-50859
FR Document		2015-20642

Federal Register, Volume 80 Issue 162 (Friday, August 21, 2015)

[Federal Register Volume 80, Number 162 (Friday, August 21, 2015)]
[Notices]
[Page 50859]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-20642]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; NCI P01 Meeting II.
    Date: October 15-16, 2015.
    Time: 8:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 
Wisconsin Avenue, Bethesda, MD 20814.
    Contact Person: Delia Tang, MD, Scientific Review Officer, 
Research Programs Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W602, Bethesda, MD 20892, 240-276-6456, [email protected]

    Name of Committee: National Cancer Institute Initial Review 
Group; Subcommittee I-Transition to Independence.
    Date: October 20-21, 2015.
    Time: 8:00 a.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hilton Alexandria Old Town, 1767 King Street, Alexandria, 
VA 22314.

    Contact Person: Sergei Radaev, Ph.D. Scientific Review Officer, 
Resources and Training Review Branch, Division of Extramural 
Activities, National Cancer Institute, NIH, 9609 Medical Center 
Drive, Room 7W114, Bethesda, MD 20892, 240-276-6466, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: August 17, 2015.
Melanie J. Gray,
 Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-20642 Filed 8-20-15; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 80, No. 162 / Friday, August 21, 2015 / Notices 50859

abuse, psychosis and Parkinson’s number of cells, including cells amended (5 U.S.C. App.), notice is
disease. Compounds that bind with high recovered from formalin-fixed paraffin- hereby given of the following meetings.
affinity and selectivity to D3 receptors embedded (FFPE) tissue slides of The meetings will be closed to the
can not only provide important tools patient samples. DHS has revealed a public in accordance with the
with which to study the structure and large number of potential regulatory
provisions set forth in sections
function of this receptor subtype, but elements for transcriptional regulation
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
may also have therapeutic potential in in various cell types. The application of
DNase-Seq techniques to patient as amended. The grant applications and
the treatment of numerous psychiatric
and neurologic disorders. samples can elucidate the discussions could disclose
The 4-phenylpiperazine derivatives pathophysiological mechanisms of gene confidential trade secrets or commercial
are an important class of dopamine D3 function in a variety of diseases as well property such as patentable material,
selective ligands. However, due to their as provide potentially important and personal information concerning
highly lipophilic nature, these diagnostic and prognostic information. individuals associated with the grant
compounds suffer from solubility Unfortunately, the current DNase-Seq applications, the disclosure of which
problems in aqueous media and reduced techniques require large number of cells would constitute a clearly unwarranted
bioavailability. To address this problem, and are applicable only to larger invasion of personal privacy.
a process was designed to introduce biopsies and surgical specimens. This Name of Committee: National Cancer
functionality into the carbon chain technique, called Pico-Seq, allows Institute Special Emphasis Panel; NCI P01
linker of these compounds. Compared to detection when only very small Meeting II.
currently available dopamine D3 population of cells are available, such as Date: October 15–16, 2015.
receptor ligands, the resulting rare primary tumor cells and Time: 8:00 p.m. to 5:00 p.m.
compounds show improved circulating-tumor-cells, isolated by a Agenda: To review and evaluate grant
pharmacological properties and D3 variety of methods. Pico-Seq uses applications.
selectivities but due to their more conditions capable of restoring the Place: Hyatt Regency Bethesda, One
hydrophilic nature, these derivatives are DNase I sensitivity, similar to native/ Bethesda Metro Center, 7400 Wisconsin
predicted to have improved water fresh cells, in tissue/cells from slides Avenue, Bethesda, MD 20814.
solubility and bioavailability. processed by extremely harsh Contact Person: Delia Tang, MD, Scientific
Potential Commercial Applications: conditions, such as in FFPE tissues. Review Officer, Research Programs Review
• Therapeutics for a variety of Potential Commercial Applications: Branch, Division of Extramural Activities,
psychiatric and neurologic disorders • Diagnostic and prognostic kits National Cancer Institute, NIH, 9609 Medical
• Research tools to study D3 receptor • Research kits
Center Drive, Room 7W602, Bethesda, MD
structure and function Competitive Advantages:
20892, 240–276–6456, tangd@mail.nih.gov
Competitive Advantages: • Applicable to very small number of
cells down to a single cell. Name of Committee: National Cancer
• Improved pharmacological
properties and selectivity over existing • Capable of using cells isolated by Institute Initial Review Group; Subcommittee
any of the available methods, including I-Transition to Independence.
dopamine D3 receptor ligands Date: October 20–21, 2015.
• Hydrophilic nature likely to lead to flow cytometry, biopsies, laser capture
microdissection, and even cells Time: 8:00 a.m. to 1:00 p.m.
improved water solubility and Agenda: To review and evaluate grant
bioavailability recovered from formalin-fixed paraffin-
embedded tissue slides of patient applications.
Development Stage: Early-stage; In Place: Hilton Alexandria Old Town, 1767
vitro data available samples.
Development Stage: Early-stage; In King Street, Alexandria, VA 22314.
Inventors: Amy H. Newman (NIDA),
Peter Grundt (NIDA), Jianjing Cao vitro data available Contact Person: Sergei Radaev, Ph.D.
Inventors: Keji Zhao and Tang Scientific Review Officer, Resources and
(NIDA), Robert Luedtke
Qingsong (NHLBI) Training Review Branch, Division of
Intellectual Property: HHS Reference
Intellectual Property: HHS Reference Extramural Activities, National Cancer
No. E–128–2006/0—US Patent No.
No. E–254–2014/0—US Provisional Institute, NIH, 9609 Medical Center Drive,
8,748,608 issued June 10, 2014 Application No. 62/118,574 filed
Licensing Contact: Betty B. Tong, Room 7W114, Bethesda, MD 20892, 240–
February 20, 2015 276–6466, sradaev@mail.nih.gov.
Ph.D.; 301–594–6565; tongb@ Licensing Contact: Cristina
mail.nih.gov (Catalogue of Federal Domestic Assistance
Thalhammer-Reyero, Ph.D., M.B.A.; Program Nos. 93.392, Cancer Construction;
Collaborative Research Opportunity: 301–435–4507; ThalhamC@mail.nih.gov
The National Institute on Drug Abuse, 93.393, Cancer Cause and Prevention
Medications Discovery Research Dated: August 18, 2015. Research; 93.394, Cancer Detection and
Branch, is seeking statements of Richard U. Rodriguez, Diagnosis Research; 93.395, Cancer
capability or interest from parties Acting Director, Office of Technology Treatment Research; 93.396, Cancer Biology
interested in collaborative research to Transfer, National Institutes of Health. Research; 93.397, Cancer Centers Support;
further develop, evaluate, or [FR Doc. 2015–20694 Filed 8–20–15; 8:45 am] 93.398, Cancer Research Manpower; 93.399,
commercialize 4-phenylpiperazine BILLING CODE 4140–01–P Cancer Control, National Institutes of Health,
derivatives as dopamine D3 selective HHS)
ligands. For collaboration opportunities, Dated: August 17, 2015.
please contact Vio Conley, M.S. at 240– DEPARTMENT OF HEALTH AND Melanie J. Gray,
276–5531 or conleyv@mail.nih.gov. HUMAN SERVICES
rmajette on DSK7SPTVN1PROD with NOTICES

Program Analyst, Office of Federal Advisory
Genome Wide DNase I Hypersensitive National Institutes of Health Committee Policy.
Sites Detection in Formalin-Fixed [FR Doc. 2015–20642 Filed 8–20–15; 8:45 am]
Paraffin-Embedded Single Cells National Cancer Institute; Notice of BILLING CODE 4140–01–P
Closed Meetings
Description of Technology: A method
of detecting DNase I hypersensitive sites Pursuant to section 10(d) of the
((DHS) in a single cell or very small Federal Advisory Committee Act, as

VerDate Sep<11>2014 15:07 Aug 20, 2015 Jkt 235001 PO 00000 Frm 00041 Fmt 4703 Sfmt 9990 E:\FR\FM\21AUN1.SGM 21AUN1

Document Created: 2018-02-23 11:01:08
Document Modified: 2018-02-23 11:01:08

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		October 15-16, 2015.
FR Citation		80 FR 50859

80 FR 50859 - National Cancer Institute; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 80, Issue 162 (August 21, 2015)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health